
The BRCA1 and BRCA2 genes are known to significantly increase the chances of a woman developing cancer and it was …

It’s been a terrible week for Alzheimer’s disease research, after Pfizer shuttered its neuroscience unit and

Novartis has been looking to find someone to fill the shoes of Bruno Strigini since it was revealed that he …

Teva’s current crisis is built upon problems that run deep into the company, after numerous acquisitions left it bloated and …

AstraZeneca and its biologics R&D unit MedImmune have announced that their drug Fasenra (benralizumab) has received approval from the European …

The AIDS Healthcare Foundation (AHF) has strongly criticised Gilead prices increases across the board for its HIV and AIDS treatment, …

It has been reported that Swiss food giant Nestle has pulled out in front as the top bidder for Merck …

The struggles of the NHS this winter are no secret, especially after being front and centre of the first Prime …

Dr Aidan Murphy has been named by Ipsen’s new Executive Vice President, Technical Operations, succeeding Jonathan Barnsley who retired at …

Danish pharmaceutical firm Lundbeck has signed a separate licensing and research collaboration agreement with Tennessee’s Vanderbilt University to develop a …

It’s been a gloomy period for research into Alzheimer’s disease treatments in the last week, Pfizer announced it would be …

Bayer and Johnson & Johnson have managed to avert a payout of $27.8 million after a Pennsylvania state court judge …

Patient adherence is a big issue across the healthcare system, where individuals, even with the most serious conditions, do not …

Researchers from RMIT University in Australia were tasked with developing a more effective breath test for determining what was happening …

Sri Lanka is set to build its first-ever exclusive pharmaceutical manufacturing zone, it has emerged. The State Pharmaceuticals Manufacturing Corporation …

A collaboration that sees six pharma players come together to fund the sequencing of a particular section of DNA of …

Shire has revealed that it now plans to move forward by separating its operations into two distinct divisions: rare disease …

As part of Theresa May’s well-publicised cabinet reshuffle, many were expecting Jeremy Hunt to move from his position as Secretary …

Biopharmaceutical firm and cellular immunotherapy specialist Juno Therapeutics has named Cindy Elkins as its new Chief Information Officer, where she …

The signs were already there for Axovant Sciences’ key drug, intepirdine, when it posted poor results from a recent study …